

## LIST OF ABBREVIATIONS

BLT	Buoyancy lag time
CRDDS	Controlled release drug delivery systems
CR	Controlled release
DDS	Drug delivery systems
DF	Dosage forms
FDDS	Floating drug delivery systems
FLT	Floating lag time
GI	Gastrointestinal
GIT	Gastrointestinal tract
GRDDS	Gastroretentive drug delivery systems
GRDFs	Gastroretentive dosage forms
GRT	Gastric retention time
HPMC	Hydroxypropyl methyl cellulose
IVIVC	<i>In vitro</i> – <i>in vivo</i> correlation
TFT	Total floating time
UV	Ultra violet
WU	Water uptake
HPMC	Hydroxymethylpropyl cellulose
CP	Carbopol
mg	Milligram
µg	Microgram

## List of Figures

Fig. No.	Title	Page no.
1.	Plasma level profiles following conventional and CR dosing	2
2.	Pictorial representation of the anatomy of stomach	4
3.	Pictorial representation of the typical motility patterns in fasting state	5
4.	Flow chart depicting classification of GRDDS	9
5.	A colloidal gel barrier system	12
6.	The gelatinous polymer barrier formation as a result from hydrophilic polymer swelling. Drug is released by diffusion and erosion	13
7.	Interaction of a mucoadhesive drug delivery system with the mucus layer on the gastrointestinal surface epithelium	17
8.	Schematic localization of an intragastric floating system and a high density system in the stomach	23
9.	Overview of QbD	40
10.	System with controlled input variable(s) X, uncontrolled input variable(s) U, transfer function T, and output variable(s) Y	43
11.	Illustration of quantitative factors and the factor space. The axes for the natural variables, compression time and force are labeled $U_1$ , $U_2$ and the axes of the corresponding coded variables are labeled as $X_1$ and $X_2$	45
12.	Inter-relationship between knowledge, design and control spaces	46
13.	Five steps strategy of formulating DDS using FbD	48
14.	Digrammatic representation of experimental design	49
15.	Position of the design points in (a) $2^2$ factorial design; and (b) star design	50
16.	Representation of central composite design (a) rectangular domain with $\alpha=1$ ; (b) spherical domain with $\alpha = 1.414$	50
17.	Representation of (a) a face centered CCD; (b) a circumscribed rotatable CCD; (c) an inscribed rotatable CCD	50
18.	Diagrammatic representation of inner $2^3$ and outer $2^2$ arrays for Taguchi robust design with “I” as the inner array and “E” as the outer array	51
19.	Diagrammatic representation of a Box-Behnken Design for three factors	52
20.	Contour lines (a) maximum; (b) saddle point; (c) ridge; and (d) rising ridge	53
21.	A typical response surface plotted between two factors $X_1$ and $X_2$ and a response variable Y	53

22.	A bird's eye view of the overall strategy for optimization of drug formulations	58
23.	Structural formula of HPMC	65
24.	Structural formula of Diltiazem hydrochloride	68
25.	Bioadhesive Strength measuring device	123
26.	Calibration curve of diltiazem hydrochloride in 0.1 N HCl	127
27.	Bioadhesive strength of formulations prepared as per experimental design	131
28.	Effect of HPMC and carbopol on the floating time	133
29.	Percent drug released vs. time plot of all floating bioadhesive formulations prepared as per CCD	150
30.	Rate of drug released vs. mid point of time interval plot of all floating bioadhesive formulations prepared as per CCD.	150
31.	(a) Response surface plot showing the influence of CP and HPMC on the value of $t_{60\%}$ of floating bioadhesive tablets of diltiazem hydrochloride.	152
	(b) Contour plot showing the influence of CP and HPMC on the value of $t_{60\%}$ of floating bioadhesive tablets of diltiazem hydrochloride.	152
32.	(a) Response surface plot showing the influence of CP and HPMC on the value of $Q_{16hrs}$ of floating bioadhesive tablets (b) Contour Plot showing the influence of CP and HPMC on the value of $Q_{16hrs}$ of floating bioadhesive tablets.	153
33.	(a) Response surface plot showing the influence of CP and HPMC on the value of $\sigma$ of floating bioadhesive tablets of diltiazem hydrochloride.	154
	(b) Contour plot showing the influence of CP and HPMC on the value of $\sigma$ of floating bioadhesive tablets of diltiazem hydrochloride.	154
34.	(a) Response surface plot showing the influence of CP and HPMC on the value of $T_b$ of floating bioadhesive tablets of diltiazem hydrochloride	155
	(b) Contour plot showing the influence of CP and HPMC on the value of $T_b$ of floating bioadhesive tablets of diltiazem hydrochloride.	155
35.	Overlay plot depicting the design space for locating the floating bioadhesive optimized formulation of diltiazem hydrochlorid (Dilt -OPT)	158
36.	Linear and residual plots between predicted and observed value of $Q_{16hrs}$	171
37.	Linear and residual plots between predicted and observed value of $\sigma$	171
38.	Linear plots and residual between predicted and observed value of	171

	$T_b$	
39.	Linear and residual plots between predicted and observed value of $t_{60\%}$	171
40.	X- Ray Images of Rabbits showing floating-bioadhesive tablets in the stomach of rabbit after 4 hours	173
41.	X- Ray Images of Rabbits showing floating-bioadhesive tablets in the stomach of rabbit after 8 hours	173
42.	Anterior static scintigraphic images of the stomach of healthy volunteer-1, following oral administration of $^{99m}\text{Tc}$ -labelled optimized formulation depicting gastric emptying time.	174
43.	Anterior static scintigraphic images of the stomach of healthy volunteer-2, following oral administration of $^{99m}\text{Tc}$ -labelled optimized formulation depicting gastric emptying time.	174
44.	SEM image of floating bead	185
45.	Cumulative % drug released vs. time plot of all formulations prepared as per CCD	193
46.	(a) Response surface plot showing the influence of sodium alginate and oil on the value of Q of floating beads of diltiazem hydrochloride	195
	(b) Contour plot showing the influence of sodium alginate and oil on the value of Q of floating beads of diltiazem hydrochloride.	195
47.	(a) Response surface plot showing the influence of sodium alginate and oil on the value of $T_b$ of floating beads of diltiazem hydrochloride.	196
	(b) Contour plot showing the influence of sodium alginate and oil on the value of $T_b$ of floating beads of diltiazem hydrochloride.	196
48.	(a) Response surface plot showing the influence of sodium alginate and oil on the value of bead size of floating beads of diltiazem hydrochloride.	197
	(b) Contour plot showing the influence of sodium alginate and oil on the value of S of floating beads of diltiazem hydrochloride.	197
49.	(a) Response surface plot showing the influence of sodium alginate and oil on the value of EE of floating beads of diltiazem hydrochloride.	198
	(b) Contour plot showing the influence of sodium alginate and oil on the value of EE of floating beads of diltiazem hydrochloride.	198
50.	(a) Response surface plot showing the influence of sodium alginate and oil on the value of $t_{60\%}$ of floating beads of diltiazem hydrochloride.	199
	(b) Contour plot showing the influence of sodium alginate and oil on the value of $t_{60\%}$ of floating beads of diltiazem hydrochloride.	199

51.	Design space overlay plot depicting the location of optimized formulation (D-OPT)	206
52.	Linear and residual plots of EE	20
53.	Linear and residual plots of Q	208
54.	Linear and residual plot of $T_b$	208
55.	Linear and residual plot of S	208
56.	Linear and residual plot of $t_{60\%}$	208
57.	Anterior static scintigraphic images of the stomach of healthy volunteer-1, following oral administration of $^{99m}\text{Tc}$ -labelled optimized formulation depicting gastric emptying time.	210
58.	Anterior static scintigraphic images of the stomach of healthy volunteer-2, following oral administration of $^{99m}\text{Tc}$ -labelled optimized formulation depicting gastric emptying time.	210

## List of Tables

Table No.	Title of table	Page no.
1.	Marketed Preparations of gastroretentive dosage forms	26
2.	Diffusional exponents corresponding to different transport systems with customary geometrical forms	31
3.	Patents on GR dosage forms	37
4.	FbD formulation optimization reports on compressed oral sustained release matrices formulated using natural or semisynthetic polymers	59
5.	FbD formulation optimization reports on oral sustained release matrices formulated using synthetic polymers	60
6.	FbD formulation optimization reports on floating drug delivery systems	62
7.	General composition of diltiazem HCl floating bioadhesive tablets during initial studies	120
8.	Factor combinations as per the chosen experimental design	121
9.	Translation of coded levels in actual units	121
10.	Composition of diltiazem HCl Floating bioadhesive tablets as per design	122
11.	Calibration curve of diltiazem hydrochloride in 0.1 N HCl	127
12.	Physical characterization of floating bioadhesive tablets	130
13.	Swelling index of formulations prepared as per experimental design	132
14.	Dissolution and statistical parameters for floating bioadhesive tablets	134
15.	Mean value of percent released, contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F1	135
16.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F2	136
17.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F3	137
18.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F4	138
19.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F5	139

20.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F6	140
21.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F7	141
22.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F8	142
23.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F9	143
24.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F10	144
25.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F11	145
26.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F12	146
27.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation F13	147
28.	Dissolution and statistical parameter of each floating bioadhesive tablet formulations	148
29.	Values of the coefficients for the polynomial equations and r for various response variables of the floating bioadhesive tablets	151
30.	Results of numerical optimization for optimized formulation of diltiazem hcl	157
31.	Feasibility search for floating bioadhesive tablets	159
32.	Grid searches for floating bioadhesive tablets	160
33.	Values of physical parameters of six validation checkpoints and optimized formulation of floating bioadhesive tablets	161
34.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation V1	162
35.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation V2	163
36.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation V3	164
37.	Mean value of percent released contribution of diffusion and relaxation, log $M_t/M_\infty$ and rates of drug release for formulation V3	165

	Mt/M $\infty$ and rates of drug release for formulation V4	
38.	Mean value of percent released contribution of diffusion and relaxation, log Mt/M $\infty$ and rates of drug release for formulation V5	166
39.	Mean value of percent released contribution of diffusion and relaxation, log Mt/M $\infty$ and rates of drug release for formulation V6	167
40.	Mean value of percent released contribution of diffusion and relaxation, log Mt/M $\infty$ and rates of drug release for formulation Dilt-OPT.	168
41.	Dissolution and statistical parameter of each floating bioadhesive tablet formulations	169
42.	Comparison of experimental results with predicted responses for validation checkpoints	170
43.	Various parameters of the optimized formulation analyzed at different time points during stability studies	172
44.	Factor combinations as per the chosen experimental design	182
45.	Translation of coded levels in actual units	182
46.	Composition of diltiazem hydrochloride floating beads	183
47.	Different physical parameters of floating beads	186
48.	Physicochemical properties of floating beads	186
49.	<i>In-vitro</i> drug release characteristics of formulation F1	188
50.	<i>In-vitro</i> drug release characteristics of formulation F2	188
51.	<i>In-vitro</i> drug release characteristics of formulation F3	189
52.	<i>In-vitro</i> drug release characteristics of formulation F4	189
53.	<i>In-vitro</i> drug release characteristics of formulation F5	190
54.	<i>In-vitro</i> drug release characteristics of formulation F6	190
55.	<i>In-vitro</i> drug release characteristics of formulation F7	191
56.	<i>In-vitro</i> drug release characteristics of formulation F8	191
57.	<i>In-vitro</i> drug release characteristics of formulation F9	192
58.	Kinetic studies of floating beads	192
59.	Values of the coefficients for the polynomial equations and r for various response variables of the floating beads	194
60.	Feasibility search for floating beads	201
61.	Grid search for floating beads	203
62.	Results of numerical optimization for optimized formulation of diltiazem	205

	hydrochloride	
63.	Values of physical parameters of six check points and optimized formulation of floating beads	206
64.	Comparison of experimental results with predicted responses for diltiazem hydrochloride floating multiple units drug delivery systems	207
65.	Various parameters of the optimized formulation analyzed at different time points during accelerated stability studies	209